Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with ADC for Patients with Resectable NSCLC By Ogkologos - July 29, 2025 444 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NeoCOAST-2 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Some People with Rectal Cancer Can Skip Radiation Before Surgery July 19, 2023 EMA Recommends Extension of Therapeutic Indications for Olaparib to Patients with... July 17, 2024 Screening for Many Cancers with One Test: Uncertainty Abounds April 21, 2022 Facing the future: “How can a 3-year old understand that her... January 12, 2022 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Fedratinib News on the Passing of the Lymphedema Treatment Act! Targeted Therapy, Driven by Comprehensive Genomic Profiling and Molecular Tumour Board,... Blood test could tailor treatment after surgery
